228 related articles for article (PubMed ID: 28694230)
1. Pharmacokinetics of piperacillin-tazobactam in plasma, peritoneal fluid and peritoneum of surgery patients, and dosing considerations based on site-specific pharmacodynamic target attainment.
Murao N; Ohge H; Ikawa K; Watadani Y; Uegami S; Shigemoto N; Shimada N; Yano R; Kajihara T; Uemura K; Murakami Y; Morikawa N; Sueda T
Int J Antimicrob Agents; 2017 Sep; 50(3):393-398. PubMed ID: 28694230
[TBL] [Abstract][Full Text] [Related]
2. Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics.
Kobayashi I; Ikawa K; Nakamura K; Nishikawa G; Kajikawa K; Yoshizawa T; Watanabe M; Kato Y; Zennami K; Kanao K; Tobiume M; Yamada Y; Mitsui K; Narushima M; Morikawa N; Sumitomo M
J Infect Chemother; 2015 Aug; 21(8):575-80. PubMed ID: 26050020
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of intraperitoneal piperacillin/tazobactam in patients on peritoneal dialysis with and without pseudomonas peritonitis.
Zaidenstein R; Weissgarten J; Dishi V; Koren M; Soback S; Gips M; Averbuch Z; Simantov R; Assulin E; Golik A
Perit Dial Int; 2000; 20(2):227-31. PubMed ID: 10809248
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections.
Chen R; Qian Q; Sun MR; Qian CY; Zou SL; Wang ML; Wang LY
Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):363-72. PubMed ID: 25894901
[TBL] [Abstract][Full Text] [Related]
5. A pilot study on pharmacokinetic/pharmacodynamic target attainment in critically ill patients receiving piperacillin/tazobactam.
Martínková J; Malbrain ML; Havel E; Šafránek P; Bezouška J; Kaška M
Anaesthesiol Intensive Ther; 2016; 48(1):23-8. PubMed ID: 26588478
[TBL] [Abstract][Full Text] [Related]
6. Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review.
Yusuf E; Spapen H; Piérard D
J Crit Care; 2014 Dec; 29(6):1089-95. PubMed ID: 25179412
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of flomoxef in plasma, peritoneal fluid, peritoneum, and subcutaneous adipose tissue of patients undergoing lower gastrointestinal surgery: Dosing considerations based on site-specific pharmacodynamic target attainment.
Hirano T; Ohge H; Ikawa K; Uegami S; Watadani Y; Shigemoto N; Yoshimura K; Kitagawa H; Kaiki Y; Morikawa N; Takahashi S
J Infect Chemother; 2023 Feb; 29(2):186-192. PubMed ID: 36341996
[TBL] [Abstract][Full Text] [Related]
8. Ceftolozane-Tazobactam Pharmacokinetics in the Abdominal Tissue of Patients Undergoing Lower Gastrointestinal Surgery: Dosing Considerations Based on Site-Specific Pharmacodynamic Target Attainment.
Yoshimura K; Ohge H; Ikawa K; Uegami S; Watadani Y; Shigemoto N; Hirano T; Kitagawa H; Kaiki Y; Morikawa N; Takahashi S
Infect Dis Ther; 2023 Jan; 12(1):193-207. PubMed ID: 36418742
[TBL] [Abstract][Full Text] [Related]
9. Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.
Roger C; Cotta MO; Muller L; Wallis SC; Lipman J; Lefrant JY; Roberts JA
Int J Antimicrob Agents; 2017 Aug; 50(2):227-231. PubMed ID: 28689876
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of cefmetazole in plasma, peritoneal fluid, peritoneum, and subcutaneous adipose tissue of patients scheduled for lower gastrointestinal surgery: Dosing considerations based on site-specific pharmacodynamic target attainment.
Kaiki Y; Ohge H; Ikawa K; Uegami S; Watadani Y; Shigemoto N; Hirano T; Yoshimura K; Kitagawa H; Morikawa N; Takahashi S
J Infect Chemother; 2023 Mar; 29(3):309-315. PubMed ID: 36549644
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam during high volume haemodiafiltration in patients with septic shock.
Tamme K; Oselin K; Kipper K; Tasa T; Metsvaht T; Karjagin J; Herodes K; Kern H; Starkopf J
Acta Anaesthesiol Scand; 2016 Feb; 60(2):230-40. PubMed ID: 26830215
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration.
Varghese JM; Jarrett P; Boots RJ; Kirkpatrick CM; Lipman J; Roberts JA
Int J Antimicrob Agents; 2014 Apr; 43(4):343-8. PubMed ID: 24612982
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam.
Kim MK; Capitano B; Mattoes HM; Xuan D; Quintiliani R; Nightingale CH; Nicolau DP
Pharmacotherapy; 2002 May; 22(5):569-77. PubMed ID: 12013355
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.
Awissi DK; Beauchamp A; Hébert E; Lavigne V; Munoz DL; Lebrun G; Savoie M; Fagnan M; Amyot J; Tétreault N; Robitaille R; Varin F; Lavallée C; Pichette V; Leblanc M
Pharmacotherapy; 2015 Jun; 35(6):600-7. PubMed ID: 26095008
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
Butterfield JM; Lodise TP; Beegle S; Rosen J; Farkas J; Pai MP
J Antimicrob Chemother; 2014 Jan; 69(1):176-9. PubMed ID: 23869050
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.
Sturm AW; Allen N; Rafferty KD; Fish DN; Toschlog E; Newell M; Waibel B
Pharmacotherapy; 2014 Jan; 34(1):28-35. PubMed ID: 23864417
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH).
van der Werf TS; Mulder PO; Zijlstra JG; Uges DR; Stegeman CA
Intensive Care Med; 1997 Aug; 23(8):873-7. PubMed ID: 9310805
[TBL] [Abstract][Full Text] [Related]
18. Measurement of piperacillin plasma concentrations in cancer patients with suspected infection.
Rachow T; Schlüter V; Bremer-Streck S; Lindig U; Scholl S; Schlattmann P; Kiehntopf M; Hochhaus A; von Lilienfeld-Toal M
Infection; 2017 Oct; 45(5):629-636. PubMed ID: 28516432
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.
Nichols K; Chung EK; Knoderer CA; Buenger LE; Healy DP; Dees J; Crumby AS; Kays MB
Antimicrob Agents Chemother; 2016 Jan; 60(1):522-31. PubMed ID: 26552978
[TBL] [Abstract][Full Text] [Related]
20. Target attainment with continuous dosing of piperacillin/tazobactam in critical illness: a prospective observational study.
Aardema H; Nannan Panday P; Wessels M; van Hateren K; Dieperink W; Kosterink JGW; Alffenaar JW; Zijlstra JG
Int J Antimicrob Agents; 2017 Jul; 50(1):68-73. PubMed ID: 28501674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
